Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00232531|
Recruitment Status : Unknown
Verified September 2006 by University of Oxford.
Recruitment status was: Active, not recruiting
First Posted : October 4, 2005
Last Update Posted : January 29, 2007
AIM 1 will test the hypothesis that elevation of high-density lipoprotein (HDL) through treatment with Niaspan will accelerate the regression of atherosclerotic plaque in patients with established atherosclerosis. The investigators will therefore study patients with atherosclerosis in the aorta and carotid artery. Plaque quantification will be with magnetic resonance imaging (MRI).
AIM 2 will assess the ability of Niaspan to improve endothelial function in patients with coronary artery disease and type II diabetes mellitus, who typically have low high-density lipoprotein cholesterol (HDL-C), and high risk of cardiovascular events.
|Condition or disease||Intervention/treatment|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||70 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Cardiovascular Magnetic Resonance Evaluation of the Effects of Niaspan on Regression of Atherosclerosis and Restoration of Endothelial Function|
|Study Start Date :||September 2004|
|Estimated Study Completion Date :||February 2009|
- Regression of artheriosclerotic plaque measured using functional magnetic resonance imaging.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00232531
|Oxford, United Kingdom|
|Principal Investigator:||Robin P Choudhury, DM, MRCP||University of Oxford|